Effectiveness of steroids vs placebo in preventing upper airway obstruction after extubation in critically-ill children: rationale and design of a multicentric, double-blind, randomized study.

CURRENT STATUS: UNDER REVIEW

Gema Manrique
Gregorio Marañón General University Hospital

Laura Butragueño Laiseca
Gregorio Marañón General University Hospital

ORCiD: 0000-0001-5430-0488

Rafael González
Gregorio Marañón General University Hospital

Corsino Rey
Central Hospital of Asturias

Zuriñe Martínez
Vall d’Hebron University Hospital

Javier Gil
Cruces University Hospital

Antonio Rodriguez
University Hospital of Santiago de Compostela

Cecilia Martínez
Gregorio Marañón General University Hospital

Silvia Manrique
Gregorio Marañón General University Hospital

Jesús López-Herce pielvi@hotmail.com

Corresponding Author

ORCiD: 0000-0001-6105-9178

DOI:
SUBJECT AREAS

Internal Medicine  Integrative & Complementary Medicine

KEYWORDS

Steroids, Dexamethasone, Stridor, Upper airway obstruction, Children, Extubation.
Abstract

Background Post-extubation upper airway obstruction (UAO) is a frequent complication causing stridor and respiratory distress, which occasionally may require reintubation, thereby increasing morbidity and mortality rates. Contradictory results have been obtained in studies assessing the effectiveness of steroids in preventing post-extubation UAO, and the available evidence is limited. We designed a multicentric randomized, placebo-controlled study to explore the effectiveness of dexamethasone in preventing post-extubation UAO in children.

Methods A multicentric, prospective, double-blind, randomized, placebo-controlled, phase IV clinical trial has been designed. The sample will include pediatric patients between 1 month and 16 years of age who have been intubated for more than 48 hours. Patients with airway disorders or who have received steroids within the last seven days will be excluded. Patients will be randomized to receive either placebo or a therapy with dexamethasone 0.25 mg/kg every 6 hours to be started 6-to-12 hours prior to extubation, to a total of four doses. Randomization will be performed at a 1:1 ratio. Follow-up of patients will be carried out for 48 h after extubation. The main objective of this study is to assess the reduction of UAO symptoms following extubation, as measured using the Taussig scale. Secondary objectives include assessing the decrease in the incidence of reintubation, evaluating the use of additional therapies for upper airway obstruction, and monitoring dexamethasone potential side effects.

Discussion The results of this study will contribute to the existing evidence on prophylaxis for post-extubation airway obstruction.

Background

Critically-ill pediatric patients frequently require endotracheal intubation. Post-extubation upper airway obstruction (UAO) is a common complication that affects up to a third of
patients who require endotracheal intubation [1–3].

Laryngeal edema is more frequent and severe in children than in adults due to the small diameter of their airways. Indeed, this type of edema in children affects the subglottal region more frequently than the glottal region[2,4]. Signs of airway obstruction include stridor and respiratory distress, which require reintubation in 6-13% of patients [1–3]. Risk factors related to post-extubation UAO include underlying respiratory or neurological disease, prolonged intubation (more than 36-48h), reintubation, a young age (≤ 24 months of age), or infants weigh less than 5 kilograms [1,2].

The obstruction of the upper airways has significant effects on the evolution of the patient. This complication may increase morbidity and mortality, length of hospital stay, duration of mechanical ventilation and healthcare-related costs, especially when the patient requires reintubation [1,2,5,6].

Steroids are one of the most widely used therapies for post-extubation UAO, as they have anti-inflammatory effects, thereby reducing the risk for laryngeal edema and airway obstruction. A range of steroids such as hydrocortisone, methylprednisolone and dexamethasone have been used for the prevention and management of post-extubation UAO [4,7]. Contradictory results have been obtained in studies assessing the effectiveness of steroids in preventing post-extubation UAO [5–10].

A recent meta-analysis [7] of studies in adult patients with and without UAO risk factors receiving different regimens of steroids showed that steroids reduce the incidence of upper airway complications and reintubation in high-risk patients.

Studies in pediatric patients are based on widely heterogeneous samples of patients, doses and timing of prophylactic therapy ranging from one hour to 24 hours prior to extubation [4,7].

In studies on the use of dexamethasone in children, a variety of regimens have been used
versus placebo. Some authors report a decrease in the incidence of stridor [5,8], whereas two studies show a reduction in the incidence of reintubation [8,9]. A study in neonates concluded that dexamethasone reduced the risk for reintubation [10]. In contrast, this benefit has not been proven in other studies in children [11] and neonates [12]. Baranwal et al [3] compared two regimens in high-risk pediatric patients: starting dexamethasone therapy 6 hours vs 24 hours before extubation. The authors found that the 24-h regimen reduced significantly the incidence of UAO, as compared to the 6-h regimen. A Cochrane's systematic review [4] concluded that the effectiveness of steroids in preventing UAO in children has not been sufficiently demonstrated, and further studies are needed to assess its potential benefits, especially in high-risk patients. It is important that the study sample is composed of the patients who are more likely to benefit from steroids, as their use involves certain side effects such as hyperglycemia, hypertension, infection and digestive bleeding [4,7].

In light of the lack of consistent evidence, we designed a randomized study to compare the effectiveness of dexamethasone vs placebo in the prevention of post-extubation UAO in high-risk pediatric patients (> 48 hours intubated).

The main objective of this study is to explore whether dexamethasone is effective in preventing and reducing the severity of UAO symptoms in critically-ill children vs. placebo. Secondary objectives include investigating whether dexamethasone reduces the incidence of reintubation and evaluating the potential secondary effects associated with this medication.

Methods

STUDY DESIGN

This is a multicentric, prospective, double-blind, randomized, placebo-controlled, phase IV clinical trial. Five pediatric intensive care units of hospitals located in Spain will
participate in the study. The study protocol was developed in accordance with the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) checklist (Additional file 1). The study was registered with the European Clinical Trials Register under number 2009-016596-30 in May 2010.

STUDY POPULATION

The sample will include children between 1 month and 16 years of age admitted to the ICU who require intubation for more than 48 hours, regardless of their condition. Exclusion criteria were the presence of underlying airway disease (congenital malformations, surgery, infection), the administration of steroid therapy within the last seven days, or refusal to participate in the study.

RECRUITMENT

Study candidates will be identified by a study physician, who will explain the study to parents or guardians. Written informed consent will be obtained prior to inclusion in the study. CONSORT (Consolidated Standards of Reporting Trials) flow diagram is shown in Figure 1.

RANDOMIZATION AND MASKING

Patients will be assigned to one of the two therapy groups on a 1:1 ratio by simple randomization using a randomization table on EPIDAT 3.1 (Epidat: software package for epidemiological data analysis. 2006. Consellería de Sanidade, Xunta de Galicia, España; Organización Panamericana de la Salud; Universidad CES, Colombia). The Coordinating Center will send a table for sequential randomization of patients. This table will contain the number of medication that has been assigned to each patient. The treatment group will not be detailed in the randomization table. This table will also include a number of reserve medication for use in case of deterioration, loss, or if the drug is rendered unusable. The Pharmacy Unit of the Coordinating Center will send treatment-arm
assignments labeled and blinded as established in the randomization table for each center.

The labeling and blinding of medication kits will be performed by the Pharmacy Unit of the Coordinating Center, which will keep an open record of these kits and their composition. This record will be coded and stored by the pharmacist of the Coordinating Center responsible for the labeling and submission of samples.

In case of severe or unexpected adverse events related to the medication, the Principal Investigator will require the responsible pharmacist to unblind the codes identifying the sample. The Principal Investigator will be informed so that timely action can be taken. The unblinding of any code will be recorded by the pharmacist responsible for sample blinding.

**INTERVENTION**

The treatment group will receive intravenous 0.25 mg/kg/dose (to a maximum of 8 mg) every 6 hours, for a total of 4 doses. The first dose will be administered between 6 and 12 hours prior to extubation. The placebo group will be administered saline 0.9%. The study medication will have the same aspect and characteristics than placebo and both will be administered in the same way. Dose adjustment, discontinuance or reinitiation of treatment will not be allowed. Inspections will be performed to ensure that the treatment is being administered adequately.

**DATA COLLECTION AND ASSESSMENT OF EFFICACY**

On inclusion, demographic (age, sex and weight) and clinical data will be collected, as follows:

Diagnosis (six diagnostic groups will be established): surgery, lower airway obstruction, neurological disease, sepsis, trauma and other diagnosis.

Assessment of severity: the clinical status of the patient will be assessed using PIM2, PRIMS 3 and PELOD scores prior to extubation.

Size and type of endotracheal tube (cuffed or uncuffed).

Route of intubation (oral, nasal).

Previous need for endotracheal tube replacement.
Previous airway endoscopies.
Respiratory infection confirmed by endotracheal aspirate culture.
Presence of blood in endotracheal aspirate.
Duration of endotracheal intubation prior to extubation (days).

The primary endpoint is the occurrence of UAO symptoms within 48 hours after extubation.

A record of the following variables will be kept at 15 minutes, 1h, 2h, 6h, 12h, 24h and 48 hours after extubation:

1. UAO Taussig score, a clinical scoring system for the assessment of UAO severity; evaluating stridor, retractions, inflow of air into the lungs, cyanosis and consciousness. Presence of inspiratory stridor.

2. Need for and frequency of additional therapies for respiratory distress: adrenaline or nebulized budesonide, intravenous steroids, heliox or non-invasive ventilation.

3. Hemodynamic (blood pressure, heart rate) and respiratory (peripheral oxygen saturation, respiratory rate) parameters.

4. Arterial pCO$_2$ and pO$_2$ and glycemia. Blood samples will not be routinely collected, they will be drawn only for clinical purpose.

5. Need for reintubation, time point and cause.

6. Presence of digestive bleeding.

7. Occurrence of infection.

The timing of parameter recording is shown in Table 1.
| Tests                                      | Screening | First visit prior to extubation | Visits 2 to 8 |
|-------------------------------------------|-----------|---------------------------------|---------------|
| Assessment of eligibility                 |           |                                 |               |
| Informed consent                          | X         |                                 |               |
| Inclusion and exclusion criteria          | X         |                                 |               |
| Anamnesis                                 | X         |                                 |               |
| Assessment of safety                      |           |                                 |               |
| Physical examination                      | X         | X                               | X             |
| Vital signs                               | X         | X                               | X             |
| Assessment of adverse events              | X         | X                               |               |
| Previous and current medications         | X         | X                               | X             |
| Assessment of efficacy<sup>a</sup>        |           |                                 |               |
| Vital signs                               | X         | X                               | X             |
| Stridor                                   | X         | X                               | X             |
| Taussig scale                             | X         | X                               |               |
| Reintubation                              | X         |                                 |               |
| Other assessments                         |           |                                 |               |
| Other medications                         | X         |                                 |               |
| Deliveries of medication                  |           |                                 |               |
| Randomization and dispensing of the medicine | X   |                                 |               |
| Contact with the randomized-dispensing center | X   |                                 |               |

Table 1. SPIRIT Schedule of Events Timeline: enrolment, assessment of safety, assessment of efficacy, and dispensing of the medicine. Visits 2 to 8, respectively: 15 minutes following extubation, 1 h, 2 h, 6 h, 12 h, 24 h and 48 h after extubation.
EVALUATION OF SAFETY

The occurrence of adverse events from inclusion to study completion will be recorded for all patients. Severe adverse events during hospital stay will be reported to the Study Coordinator and Promotor. In case of occurrence of severe adverse events, follow-up will be performed until remission or until a diagnosis is made and its association with the study medication is established.

A severe adverse event is defined as any adverse event that the patient's treating physician considers to require treatment on the basis of the characteristics and clinical status of the patient. Severe hyperglycemia is any glycemia > 200 mg/dl that persists for more than 6 hours and/or physicians consider to require treatment on the basis of the clinical status of the patient.

Any unused medication will be disposed in accordance with the protocol established by the Pharmacy Unit in collaboration with the Unit of Environmental Management of the Coordinating center, in compliance with ISO 14.001. Upon study completion, any unused or partially used medication will be sent back to the Coordinating Center.

SAMPLE SIZE

The estimated incidence of moderate-to-severe UAO symptoms is approximately 30%. To detect a 25-to-10% reduction of breathing distress secondary to UAO with a statistical power of 80% and an alpha risk of 5%, we estimated that 100 patients would be needed in each study arm.

STATISTICS

Categorical variables will be expressed as frequencies and percentages. Normality of continuous data will be assessed by the Kolmogorov-Smirnov test. Continuous variables will be expressed as mean values and SD, or as median values and interquartile range. The association between categorical variables will be assessed by Chi-squared test or
Pearson's coefficient, or by Fisher's exact test, as appropriate, based on the sample size. Continuous variables will be compared by Student's t-test or Mann-Whitney U test. In comparisons of values with respect to time, Student's t-test of repeated measures or Wilcoxon test will be performed, as appropriate. Per protocol analysis will be performed. Bilateral statistical tests will be used at a 5% level of significance. Statistical analysis will be performed using SPSS version 20 (SPSS Inc, Chicago, USA).

DATA PROCESSING

Data from each patient will be collected and anonymized by a study member in a data log. Each study center will send their data logs to the Coordinating Center. The Principal Investigator will enter data from data logs into a single database for all study patients. A preliminary study will be performed when 50% of the required sample has been reached. Only the Principal Investigator will have access to unmasked data and preliminary study results. The study will only be interrupted if the incidence of UAO or the incidence of severe adverse events is significantly higher in the steroid treatment group as compared to the placebo group.

The final analysis will be carried out when the sample size has been reached.

Discussion

Post-extubation upper airway obstruction is a common complication that affects up to a third of patients, causing stridor and respiratory distress that require reintubation in 6-13% of patients [1-3].

There is no conclusive evidence on the effectiveness of steroids in preventing post-extubation upper airway obstruction in pediatric patients[4]. If steroids were proven to be effective, they would become the standard treatment for those patients. This would help reduce morbidity and mortality, the length of hospital stay, the duration of mechanical ventilation and hospital costs [1,2,5,6].
On the basis of the limited evidence currently available, we designed a multicentric, randomized, double-blind study. The primary endpoints are post-extubation UAO symptoms, as they reflect the effects of steroids adequately. Reintubation is the most severe consequence of extubation failure and is the factor with the most significant impact on prognosis [2,4]. Yet, as the incidence of reintubation is low, the number of patients needed for detecting differences between treatment groups would be very high. In addition, the recruitment of pediatric patients of these characteristics, who are often critically ill, is challenging. Therefore, the reduction in the incidence of reintubation was established as a secondary objective together with the occurrence of adverse events. Prolonged reintubation is one of the most significant risk factors for reintubation [1,5].

Based on the evidence provided in the literature [1,3,4,11], we decided to use intubation for > 48h as an inclusion criterion. We included other risk factors reported to be associated with UAO [1,2], namely: tube size and characteristics (cuffed or uncuffed), underlying respiratory diseases, and previous manipulation of the airway. We decided to exclude patients who have received corticoids within the last seven days because biological half-life of dexamethasone is 36 - 54 hours, and the elimination is completed (94%) after 4 half-lifes.

Steroids are used for the management of multiple diseases. Although they involve some risks, the administration of four doses of steroids for prophylaxis of the UAO after extubation is not expected to cause significant adverse events [4,7,11]. Therefore, the potential benefit of steroids would outbalance its associated risks.

The steroid most widely used for the prevention of postextubation complications is dexamethasone [4,7]. For this reason, we selected this medication for our study. However, there is variability in the timing of steroid administration prior to extubation. The intervals used range from one hour prior to extubation to 24 hours [4,7]. In several studies, the
administration of dexamethasone started 12 hours prior to extubation [5,7–9]. We decided to start the prophylactic therapy 6-12 hours before extubation. This way, it is not necessary to delay extubation until the prophylactic treatment has been completed. Delayed extubation in the final stage of mechanical ventilation withdrawal is associated with a higher risk for trauma in the upper airways as a result of tube displacement when the patient moves or secondary to a more frequent need of secretion aspiration.

The most significant limitation of this study is the high number of patients needed. The number of participating centers is not very high, and completion of the study is expected to take a long time. Indeed, as it occurs in other trials with critically-ill children, the percentage of inclusion is expected to be low due to difficulties in recruiting critically ill children. Other limitation of this study is the occurrence of other factors with impact on postextubation respiratory failure (neurologic, cardiac or respiratory diseases), which may hinder the assessment of an upper airway obstruction. Moreover, it may be difficult to distinguish adverse events related to steroids (hyperglycemia, digestive bleeding) from events related to the underlying disease and critical state of patients.

The results of this study will contribute to the existing evidence on prophylaxis for post-extubation upper airway obstruction.

**TRIAL STATUS**

Protocol version: V02, July 19, 2010. Recruitment to this study commenced in February 2013, the end of the trial is predicted for the end of 2019. Recruitment is expected to end on 31/12/2019.

**List Of Abbreviations**

UAO Upper Airway obstruction

CONSORT Consolidated Standards of Reporting Trials

SPIRIT Standard Protocol Items Recommendations for Interventional Trials
Declarations

**Ethics approval and consent to participate**

This study protocol was designed in accordance with the Declaration of Helsinki (1964) and subsequent versions. The final version of this study protocol was approved by Ethics Committee of Gregorio Marañón Hospital, Madrid, Spain (IBHGM-ECNC003-2010) and the local Ethics Committee of all participating centers. The Principal Investigator will ensure that the study is performed in accordance with laws and regulations governing the performance of clinical trials.

The rationale for using placebo is that the effectiveness of steroids has not been confirmed to date, and other medications have not been proven to be effective in preventing post-extubation complications.

The study investigator responsible for patient recruitment in each center will provide oral and written information on the study to the patients or their legal representatives when their age or clinical state prevents them from giving consent. Written informed consent will be required prior to inclusion.

The local Ethics Committees will be given access to original records and databases.

**Consent for publication**

Not applicable

**Availability of data and materials**

Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.

**Competing interests**

The authors declare that they have no competing interests. Neither participants nor investigators will receive any compensation for participating in this study.

**Funding**
This study was supported by Carlos III Health Institute (Sub-Directorate General for Research Assessment and Promotion and the European Regional Development Fund) as a non-commercial clinical trial (grant number EC11-077).

The study medication and placebo were provided by Kern-Pharma in their primary packaging as ampoules.

The investigators, patients or their families will not receive any compensation for their participation in this study.

**Authors' contributions**

JLH conceived the study, participated in the study design and revised the manuscript.

RGC participated in the study design, revised the manuscript and is responsible for data collection.

GM and LBL drafted the manuscript and are responsible for data collection.

CR, ZM, JG and AR are responsible for data collection.

CM and SM participated in the study design and are responsible for the labeling and blinding of medication kits.

All authors read and approved the final manuscript.

**Acknowledgements**

We thank the healthcare professionals of the Intensive Care and Pharmacy Units of the participating centers.

**References**

[1] S.C. Kurachek, C.J. Newth, M.W. Quasney, T. Rice, R.C. Sachdeva, N.R. Patel, J. Takano, L. Easterling, M. Scanlon, N. Musa, R.J. Brilli, D. Wells, G.S. Park, S. Penfil, K.G. Bysani, M.A. Nares, L. Lowrie, M. Billow, E. Chiochetti, B. Lindgren. Extubation failure in pediatric intensive care: A multiple-center study of risk factors and outcomes. Crit. Care Med. 2003;31:2657–64.
[2] R.G. Khemani, J. Hotz, R. Morzov, R. Flink, A. Kamerkar, P.A. Ross, C.J.L.L. Newth. Evaluating risk factors for pediatric post-extubation upper airway obstruction using a physiology-based tool. Am. J. Respir. Crit. Care Med. 2016;193:198–209.

[3] A.K. Baranwal, J.P. Meena, S.C. Singhi, J. Muralidharan. Dexamethasone pretreatment for 24 h versus 6 h for prevention of postextubation airway obstruction in children: A randomized double-blind trial. Intensive Care Med. 2014;40:1285–94.

[4] R.G. Khemani, A. Randolph, B. Markovitz. Corticosteroids for the prevention and treatment of post-extubation stridor in neonates, children and adults. Cochrane Database Syst. Rev. 2009;(3):CD001000.

[5] D. Malhotra, S. Gurcoo, S. Qazi, S. Gupta. Randomized comparative efficacy of dexamethasone to prevent postextubation upper airway complications in children and adults in ICU. Indian J Anaesth. 2009;53:442–9.

[6] T. Fan, G. Wang, B. Mao, Z. Xiong, Y. Zhang, X. Liu, L. Wang, S. Yang. Prophylactic administration of parenteral steroids for preventing airway complications after extubation in adults: Meta-analysis of randomised placebo controlled trials. BMJ. 2008;337:1088–91.

[7] A. Kuriyama, N. Umakoshi, R. Sun. Prophylactic corticosteroids for prevention of post-extubation stridor and reintubation in adults: a systematic review and meta-analysis. Chest. 2017;151:1002–10.

[8] O. Anene, K.L. Meert, H. Uy, P. Simpson, A.P. Sarnaik. Dexamethasone for the prevention of postextubation airway obstruction: a prospective, randomized, double-blind, placebo-controlled trial. Crit. Care Med. 1996;24:1666–9.

[9] D.W. Tellez, A.G. Galvis, S.A. Storgion, H.N. Amer, M. Hoseyni, T.W. Deakers. Dexamethasone in the prevention of postextubation stridor in children. J. Pediatr. 1991;118:289–94.

[10] R.J. Couser, T.B. Ferrara, B. Falde, K. Johnson, C.G. Schilling, R.E. Hoekstra.
Effectiveness of dexamethasone in preventing extubation failure in preterm infants at increased risk for airway edema. J. Pediatr. 1992;121:591–6.

[11] A.F. Saleem, S. Bano, A. Haque. Does prophylactic use of dexamethasone have a role in reducing post extubation stridor and reintubation in children?. Indian J. Pediatr. 2009;76:555–557.

[12] T.B. Ferrara, M.K. Georgieff, J. Ebert, J.B. Fisher. Routine use of dexamethasone for the prevention of postextubation respiratory distress. J. Perinatol. 1989;9:287–90.

Figures
Figure 1

CONSORT Flow Diagram

Supplementary Files

This is a list of supplementary files associated with the primary manuscript. Click to download.

SPIRIT checklist.pdf